Following a spate of large-scale pharma investments in the U.S. last year, German conglomerate Bayer is advancing its own plans to expand in America, in a move the company is framing as the ...
Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...
Already sharing the load on two biosimilar assets, Teva Pharmaceutical and Samsung Bioepis have elected to take their ...
While Foundayo’s insulin-matching potential in type 2 diabetes had been established in a topline readout earlier this year, ...
Genentech is turning up the volume on breast cancer conversations in its “About Damn Time” campaign with Breastcancer.org and ...
In three deals each worth $2 billion or more, AstraZeneca is investing in Summit Therapeutics with a focus on ivonescimab and ...
Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics ...
In Milan this week, Novo and Eli Lilly took the stage at the European Association for the Study of Diabetes 2026 meeting with ...
Come year’s end, more than 100 Novo employees reporting to the Danish drugmaker’s outpost in Plainsboro, New Jersey, will be ...
The European Commission has revoked the EU marketing authorization for Hansoh Pharma’s lung cancer drug Aumseqa (aumolertinib ...
With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. | With GLP-1s ...
Eli Lilly’s portfolio of weight loss and diabetes medications have become a dominant force in the market—but access to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results